Jump to content

Technetium (99mTc) mertiatide

From Wikipedia, the free encyclopedia
Technetium (99mTc) mertiatide
Clinical data
Trade namesTechnescan Mag3
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
3D model (JSmol)
  • C(C(=NCC(=O)[O-])[O-])N=C(CN=C(C[S-])[O-])[O-].O=[99Tc+3].[Na+].[Na+]
  • InChI=1S/C8H13N3O5S.2Na.O.Tc/c12-5(2-10-7(14)4-17)9-1-6(13)11-3-8(15)16;;;;/h17H,1-4H2,(H,9,12)(H,10,14)(H,11,13)(H,15,16);;;;/q;2*+1;;+3/p-5/i;;;;1+1
  • Key:JVYYEQVAPXSUSY-RCUQKECRSA-I

Technetium (99mTc) mertiatide is a radiopharmaceutical medication used in nuclear medicine to image the kidneys.[1] It is a renal imaging agent that is given by intravenous injection.[1]

It was approved for medical use in the United States in June 1990.[2]

Medical uses

[edit]

Technetium (99mTc) mertiatide is indicated for use in the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstruction, and calculi.[1]

Chemistry

[edit]

The active ingredient, betiatide, is reconstituted with sodium pertechnetate 99mTc injection to form technetium (99mTc) mertiatide.[1]

References

[edit]
  1. ^ a b c d e "Technescan Mag3- technescan tc 99m mertiatide injection, powder, lyophilized, for solution". DailyMed. 13 December 2022. Archived from the original on 2 February 2023. Retrieved 1 February 2023.
  2. ^ "Technescan Mag3: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 13 December 2022. Retrieved 1 February 2023.